163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study

C. Wainwright, S. McColley, P. McNally, M. Powers,F. Ratjen,J. Rayment, G. Retsch-Bogart, E. Roesch,N. Ahluwalia, A. Chin,C. Chu, M. Lu, P. Menon, S. Moskowitz, D. Waltz, T. Weinstock,F. Xuan, L. Zelazoski,J. Davies

Journal of Cystic Fibrosis（2022）

引用 0|浏览6

暂无评分

关键词

cystic fibrosis,elexacaftor/tezacaftor/ivacaftor,f508del alleles,long-term,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要